Related Experiment Videos
[Immunosuppressive treatment: surveillance, toxicity, prospects]
M Giral1, J Dantal, J P Soulillou
1ITERT Institut de transplantation et de recherche en transplantation, CHRU Hôtel-Dieu, Nantes.
La Revue Du Praticien
|February 15, 1994
Summary
New immunosuppressive drugs are being developed to improve renal transplant survival by reducing side effects and optimizing dosages. These agents offer enhanced efficacy and safety compared to older treatments.
Area of Science:
- Immunology
- Nephrology
- Pharmacology
Background:
- Historically, Imurel and glucocorticosteroids were primary agents for preventing renal allograft rejection.
- The introduction of cyclosporine A in the 1980s significantly improved transplant survival rates by 10-20%.
Purpose of the Study:
- To review the evolution of immunosuppressive therapy in renal transplantation.
- To introduce novel immunosuppressive agents and their mechanisms of action.
- To discuss the potential for combination therapy to enhance efficacy and minimize toxicity.
Main Methods:
- Literature review of immunosuppressive agents in renal transplantation.
- Analysis of the mechanisms of action for established and novel immunosuppressants.
- Discussion of clinical outcomes and side effect profiles.
Main Results:
- Established treatments (Imurel, corticosteroids, cyclosporine A) have limitations due to side effects and require close monitoring.
- New agents like FK506, rapamycin, mycophenolic acid, sodium brequinar, and 15-deoxyspergualine exhibit potent immunosuppressive activity.
- These novel agents have varied mechanisms, with some mimicking Imurel or cyclosporine A, and others having unique pathways.
Conclusions:
- Emerging immunosuppressive drugs hold promise for improving post-transplantation outcomes.
- Future research focuses on combining these agents to achieve effective immunosuppression at reduced, non-toxic dosage levels.
- Optimizing immunosuppressive regimens is crucial for long-term renal allograft survival and patient well-being.